San Diego – September 11, 2026 -- Shareholder rights firm Robbins LLP has filed a class action against Unicycive Therapeutics, Inc. (NASDAQ: UNCY) on behalf of investors who purchased the biotech's securities between December 29, 2025 and June 29, 2026, after the FDA rejected the company's kidney disease drug for a second time over unresolved manufacturing deficiencies.

Hong Kong – September 11, 2026 -- Ascletis Pharma Inc. (HKEX: 1672) has initiated a U.S. Phase I trial of ASC36, an oral amylin receptor peptide agonist for obesity, after securing Investigational New Drug clearance from the FDA.

Burlington, N.C. – September 11, 2026 -- Labcorp (NYSE: LH) has acquired MLM Medical Labs, a central and specialty laboratory provider with operations in the United States, Germany and South Africa, financial terms undisclosed.

Sugar Land, Texas – September 11, 2026 -- QuVa Pharma, Inc. has acquired a portfolio of essential sterile compounded medications from Central Admixture Pharmacy Services, Inc. (CAPS) after CAPS decided to exit the 503B sterile compounding business, the companies announced.

Cambridge, Massachusetts – September 11, 2026 -- Harbour BioMed (HKEX: 02142) and partner Windward Bio reported positive Phase 2 interim results for HBM9378/WIN378, a twice-yearly TSLP-blocking antibody, from the 147-patient POLARIS-1 asthma trial, clearing the path for two Phase 3 studies.

Laval – September 11, 2026 -- Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC) and Belgian biotech YUN have expanded their strategic partnership to Mexico and additional EMEA markets, building on a 2025 launch in Poland.

Partnership adds five new markets across EMEA and Latin America

The collaboration has extended YUN's acne-prone and eczema-prone skincare lines into the Czech Republic, Slovakia, Ukraine and Bulgaria, alongside a fresh entry into Mexico. A further rollout in Kazakhstan is expected in October 2026.

Sarasota, Fla. – September 11, 2026 -- Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT) will present at the H.C. Wainwright 28th Annual Global Investment Conference in New York City from September 14-16, 2026.

Shanghai – September 11, 2026 -- Alebund Pharmaceuticals (Jiangsu) Limited (HKEX: 09637) has received U.S. FDA clearance of its Investigational New Drug application for AP308, a first-in-class engineered recombinant IgA protease targeting IgA Nephropathy (IgAN), moving the candidate from preclinical research into clinical development.

Sarasota, Fla. – September 11, 2026 -- Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT) will present at the H.C. Wainwright 28th Annual Global Investment Conference in New York City from September 14-16, 2026.

Shanghai – September 11, 2026 -- Alebund Pharmaceuticals (Jiangsu) Limited (HKEX: 09637) has received U.S. FDA clearance of its Investigational New Drug application for AP308, a first-in-class engineered recombinant IgA protease targeting IgA Nephropathy (IgAN), moving the candidate from preclinical research into clinical development.